(PharmaNewsWire.Com, July 07, 2017 ) The Europe Bovine Respiratory Disease Treatment Market has been estimated at USD 6.13 million in 2016 and is projected to reach USD 15.56 million by 2021, at a CAGR of 20.5% during the forecast period from 2016 to 2021. There is a huge influence of bovine respiratory disease (BRD), diarrhoea, arthritis and otitis on the economically significant parameters of mortality, hot carcass weight (HCW), carcass quality, fat cover and meat colour which produces problem for the cattle production.
BRD is a complex multi-factorial disease that involves an interaction between several factors. In the current scenario body temperature has been used to determine whether treatment should be done or not. Body temperature is such an important diagnostic test that many feedlots will treat animals based upon an undifferentiated fever.
A combination of disease organisms is usually accountable for the respiratory infection and illness, but other factors also affect the animal’s health. Environmental factors, particularly transport, have been associated with BRD; weather has always been implicated in the occurrence of the disease. It has been concluded that stressful events, and others like calving or an overenthusiastic introduction to high grain rations, may precipitate cases of BRD.
The Europe bovine respiratory disease treatment market has been segmented on the basis of type of treatment into anti-infectious agents, anti-parasiticides, bronchodilators, oral rehydration fluids, non-steroidal anti-inflammatories, and mucolytic. Anti-infectious can be further sub-segmented into antibiotics and sulfas. Antibiotics and anti-inflammatory drugs are now being used for combination treatment and expected to improve the success rate of the treatment. Geographically Europe market is segmented into France, Italy, Spain, Germany and UK.
The major companies dominating this market by their products and services are Zoetis Inc., Merck & Co. Inc., Bayer Corporation, Eli Lilly & Co., Merial S.A.S, Boehringer Ingelheim Vetmedica, Novartis Animal Health, Vibrac S.A, Ceva Sante Animale and Vétoquinol S.A.
About Market Data Forecast: The publisher of this report is Market Data Forecast whose forte lies in Market research and Business Intelligence. Handling both individual and corporate clients across multiple business domains they offer syndicated/customized research to suit the client’s research objective. Their research reports section offers a wide variety of market studies ranging from all-encompassing comprehensive market studies to product specific niche markets covering North America among other regions of the global market as well. For more info kindly visit, www.marketdataforecast.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
